Is the PBM Now Your Doctor?

Charles Bennett, MD, PhD, MPP, Smart State and Frank P and Jose M Fletcher Chair, Medication Safety and Efficacy, Smart State Center of Economic Excellence, University of South Carolina and the Hollings National Cancer Institute Designated Cancer Center of the Medical University of South Carolina, Charleston, South Carolina William Hrushesky, MD, FACP, Founder and Chief […]

Treating Metastatic Malignant Melanoma, March 2016 vs April 2017

Keith Flaherty, MD, Associate Professor of Medicine, Harvard Medical School; Director of Developmental Therapeutics, Cancer Center, Massachusetts General Hospital Q: A lot has happened in the field of Metastatic Melanoma since March, 2016. In April of 2017, would your reply be any different? If so, in what way, and why? A: The only change from […]

Preventing Breast Cancer: Research Worth Watching

Susan Love, MD, MBA Chief Visionary Officer, Dr. Susan Love Research Foundation, Encino, CA Q: The goal of the Dr Susan Love Research Foundation is “… find the cause of breast cancer and prevent it now – before it starts”. What are some of the ongoing research studies that are worth watching? A: Challenging the […]

2017 USPSTF on PSA: A Bad Idea

Richard J. Ablin, Ph.D., D.Sc. (hon), Dr. h.c. Professor, Department of Pathology, University of Arizona College of Medicine, The Arizona Cancer Center and BIO5 Institute, Tucson, AZ 85724 Ronald Piana, Freelance Science Writer, Huntington, NY 11743 Q: The new draft USPSTF recommendations for rapid comment on use of PSA for screening represent a big change […]

Big 2017 Change on PSA by USPSTF

Marc B Garnick, MD, Editor in Chief, HMS Annual Report on Prostate Diseases; Gorman Professor of Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA E. David Crawford, MD, Professor of Urology and Radiation Oncology at The University of Colorado, Anschutz Campus, Aurora, CO; Medical Advisor and Founder, 3DBiopsy, Inc., Aurora, CO […]

Forget Moonshots: Biomedicine Needs an Air Traffic Control System

Jeff Shrager, PhD, Director of Research, Cancer Commons; Adjunct Professor, Symbolic Systems Program, Stanford University Q: There never seem to be enough patients matched to cancer clinical trials to quickly test new cancer treatments. Might there be a better way, using new communication technology? A: Among the few things that everyone can agree upon, one […]

Proposed FDA “Conditional Approval”- More Details

Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY Marty Tenenbaum, PhD, Founder and Chair, Cancer Commons, Los Altos, CA Follow Al Follow Marty Q: Your April 5, 2017 blog post that proposed a new “Conditional” category for FDA drug approval elicited a number of positive and negative responses. […]

Next Steps for Improving Clinical Evidence and Consistency of Payment for Precision Oncology

Kathryn A. Phillips, PhD, Professor of Health Economics and Health Services Research; Founding Director UCSF Center for Translational and Policy Research on Personalized Medicine; Dept. of Clinical Pharmacy; Institute for Health Policy Studies; Comprehensive Cancer Center University of California, San Francisco Q: Adoption and insurer coverage for precision oncology may require evidence that it can […]

Conditional Approval: Right Solution for the Wrong Problem

Shannon Brownlee, MS, Senior Vice President of the Lown Institute, a think tank in Boston. She is also co-founder of the Right Care Alliance, a social movement for transforming health care. Q: Musella and Tenenbaum recently proposed a new way, called conditional approval, for the American FDA to move potentially useful drugs to a patient […]

In Memorium: Richard E. Horowitz, M.D.

by Dr. George Lundberg Searching for Truth in Cancer Clinical Trials Richard E. Horowitz, MD, Clinical Professor of Pathology, Keck School of Medicine at USC; Emeritus Professor of Pathology, UCLA School of Medicine; Consulting Pathologist, Los Angeles Veteran’s Affairs Medical Center Q: Who has been among the strongest supporters and most constructive critics of CollabRx […]